Oculis Holding AG (OCS)
8.01
+0.05
(+0.63%)
USD |
NASDAQ |
Oct 27, 12:37
Oculis Enterprise Value : 211.49M for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 211.49M |
| October 23, 2026 | 207.78M |
| October 22, 2026 | 219.51M |
| October 21, 2026 | 205.93M |
| October 20, 2026 | 182.47M |
| October 19, 2026 | 171.98M |
| October 16, 2026 | 170.13M |
| October 15, 2026 | 176.92M |
| October 14, 2026 | 162.72M |
| October 13, 2026 | 190.50M |
| October 12, 2026 | 206.55M |
| October 09, 2026 | 234.95M |
| October 08, 2026 | 254.70M |
| October 07, 2026 | 244.82M |
| October 06, 2026 | 258.40M |
| October 05, 2026 | 248.53M |
| October 02, 2026 | 259.02M |
| October 01, 2026 | 260.87M |
| September 30, 2026 | 296.68M |
| September 29, 2026 | 283.71M |
| September 28, 2026 | 279.39M |
| September 25, 2026 | 292.36M |
| September 24, 2026 | 301.00M |
| September 23, 2026 | 336.80M |
| September 22, 2026 | 381.25M |
| Date | Value |
|---|---|
| September 21, 2026 | 346.06M |
| September 18, 2026 | 346.06M |
| September 17, 2026 | 336.19M |
| September 16, 2026 | 331.87M |
| September 15, 2026 | 341.74M |
| September 14, 2026 | 374.46M |
| September 11, 2026 | 371.99M |
| September 10, 2026 | 418.29M |
| September 09, 2026 | 428.17M |
| September 08, 2026 | 470.76M |
| September 04, 2026 | 471.38M |
| September 03, 2026 | 471.38M |
| September 02, 2026 | 462.12M |
| September 01, 2026 | 472.00M |
| August 31, 2026 | 476.32M |
| August 28, 2026 | 473.85M |
| August 27, 2026 | 487.43M |
| August 26, 2026 | 520.77M |
| August 25, 2026 | 520.15M |
| August 24, 2026 | 533.73M |
| August 21, 2026 | 527.86M |
| August 20, 2026 | 531.26M |
| August 19, 2026 | 557.80M |
| August 18, 2026 | 534.35M |
| August 17, 2026 | 531.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novartis AG | 323.28B |
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | 2.224M |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.61M |
| Total Expenses (Quarterly) | 12.61M |
| EPS Diluted (Quarterly) | -0.2059 |
| Earnings Yield | -21.96% |
| Normalized Earnings Yield | -22.64 |